This is a routine M&A communication with no new financial or deal-structure information. The preclinical data is promotional and does not change the merger timeline or terms. Monitor for the S-4 proxy statement/prospectus and stockholder vote for the next material catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 5 $1.33entry
- T+1 · 5mo ago +6.77%α +6.54% · $1.42
- T+5 · 5mo ago +5.26%α +4.69% · $1.40
- T+20 · 4mo ago +30.08%α +28.21% · $1.73
- T+60 · 3mo ago +10.53%α +6.53% · $1.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pulmatrix filed a Rule 425 communication on behalf of Eos SENOLYTIX, announcing preclinical data for PTC-2105 at the Sachs Obesity Forum. The filing reiterates the pending merger with Pulmatrix (expected Q3 2026) and highlights PTC-2105's potential in body composition and survival. No new financial terms or deal changes were disclosed.
Key Financial Metrics
Key Facts
- Eos SENOLYTIX presented preclinical data for PTC-2105 at the Sachs 2nd Annual Obesity & Cardiometabolic Innovation Forum on June 5, 2026.
- PTC-2105 demonstrated reductions in fat mass greater than GLP-1s, gains in lean mass, and improved physical function in preclinical studies.
- In naturally aged mice, 40% of the PTC-2105 25 mg/kg cohort remained alive at 146 weeks vs. 100% mortality in controls by 137 weeks (p=0.0142).
- The merger between Pulmatrix and Eos was announced March 26, 2026, expected to close in Q3 2026, with combined company trading under ticker MTXL.
- No changes to merger terms, deal value, or timeline were disclosed in this filing.
Financial Impact
No financial figures disclosed; preclinical data only.
Risk Factors
- Preclinical results may not translate to clinical outcomes.
- Merger closing is subject to stockholder approval and customary conditions.
- Combined company needs merger-associated financings to support pipeline advancement.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001493152-26-027416 |
| Document: 0001493152-26-027416-index-headers.html | 0001493152-26-027416 |
| Document: 0001493152-26-027416-index.html | 0001493152-26-027416 |
| Document: 0001493152-26-027416.txt | 0001493152-26-027416 |
Track record
21 reports on PULM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +15.29% at T+60 after the Aug 7, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 9, 20267d ago 425 Neutral 3/10 Entry $1.36 to $1.33 Now $1.33 −1.85% ▼ −1.84% −0.15% vs SPY
- Oct 30, 202617d ago 425 Neutral 3/10 Entry $1.40 to $1.38 Now $1.33 −5.00% ▼ −1.43% +1.27% vs SPY
- Oct 23, 202625d ago EFFECT Bearish 5/10 Entry $1.48 to $1.40 Now $1.33 +10.14% ▲ +5.41% +4.85% vs SPY
- Oct 22, 202625d ago 425 Neutral 4/10 Entry $1.42 to $1.41 Now $1.33 −6.34% ▼ −0.70% −1.41% vs SPY
- Oct 13, 20264w ago 425 Neutral 4/10 Entry $1.38 to $1.43 Now $1.33 −3.62% ▲ +3.62% +4.77% vs SPY
- Oct 7, 20265w ago DEFA14A Neutral 2/10 Entry $1.53 to $1.41 Now $1.33 −12.91% ▼ −7.67% −7.39% vs SPY
- Oct 2, 20266w ago S-3/A Bearish 5/10 Entry $1.48 to $1.43 Now $1.33 +10.14% ▲ +3.38% +3.80% vs SPY
- Sep 28, 20267w ago EFFECT Bearish 5/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 25, 20267w ago DEFM14A Bearish 6/10 Entry $1.59 to $1.48 Now $1.33 +16.35% ▲ +6.92% +8.12% vs SPY
- Sep 23, 20267w ago S-4/A Neutral 2/10 Entry $1.67 to $1.54 Now $1.33 −20.36% ▼ −7.78% −7.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers